RE:Next move? Sell the Cie for 0,02$/sh.Jacques4444 wrote: What is possible: they sell the 25 milliard d'actions (shares) at 0,02$ = 500 millions dollars. The buyers will have a Cie with 150 millions in bank (ty to us because we gonna pay 75 millions soon with the rights offers), no debt, a NASDAQ market, new deals (Lazard), FDA hope, RD promising, etc. TV and Cosonance will get more then 400 millions dollars from the deal, no risk, good money, For TV a loan of 230 millions gonna bring more then 100 millions in profit and for Consonance a very fast profit of more then 50% from the investment. The deal is probably already on a desk of a lawyer waiting the signal. IF SO, then a class action will be possible, they cook the book (financing) for months, a loan (TV) in a Cie (PLI) who was in a situation of possible bankrupty, transfer for shares, then sell . Equal= Turning a loan of some %/year to a profit of more then 100 millions dollars = more then 50% profit. Wow! They put the house clean, NO DEBT, plenty of cash (150 MILLIONS DOLLARS), maybe an IPO before to put a 75 millions dollars more in the bank, etc....what you think?
That's one way.
Or another way, a perhaps more normal way of growing a biotech/pharma by having a pipe line of drug candidates, developing drug candidates by running trials, getting approvals, commercialization (selling drugs).
During the process, it helps the funding if licensing or partnership deals can be secured, so that the company does not solely depend on equity offer or debt for funding.
Many nasdaq listed, clinical stage (no approved drugs) companies have much higher market cap (e.g. FGEN $3.95B or GLPG $6.23B). They both have several partnerships for their drug candidates and an extensive pipe line.
It's quite possible, imo, that Prometic can grow to market cap of $1B to 2B or more with a more cost-effective management of their balance sheet, if most or all of their near-term potential positive catalysts materialized.
So sell the company now with partially developed drug pipeline, no approved drug, no partnership, just came out of a re-financing for a possible $500M.
Or take the risk of doing proper work to grow the company and sell it in few years time with approved drug, established sales, on-going, more developed pipe line for $B market valuation plus % of primium.